Philips ePatch and AI analytics platform rolled out to 14 hospitals across Spain to monitor heart patients

Core Insights - Royal Philips has successfully launched its ambulatory cardiac monitoring service in Spain, utilizing the ePatch wearable device and AI-driven Cardiologs analytics platform to enhance detection of heart arrhythmias like atrial fibrillation (AF) [1][2][9] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation, generating sales of EUR 18.2 billion in 2023 and employing approximately 69,100 people globally [11] Product Features - The ePatch provides reliable data for up to 14 days of continuous monitoring, significantly improving the detection and diagnosis of AF, which is often undetected due to its subtle symptoms [2][3] - The device is user-friendly, allowing for quick application and integration with an analysis program, which facilitates rapid review of recordings and enhances patient comfort by eliminating cumbersome cables [3][6] Clinical Impact - The ePatch has been shown to expedite hospital discharge for patients, with 80 patients discharged in 2023, leading to a reduced average length of stay and an estimated cost reduction of €28,800 [3][9] - More than 1,500 patients are currently being monitored with the ePatch across various hospitals in Spain, helping to alleviate waiting lists that accumulated during the COVID-19 pandemic [5] Pilot Programs - Pilot projects are being conducted in major hospitals across Spain, including Madrid, Barcelona, and Bilbao, focusing on monitoring patients post-cardiac procedures and studying the relationship between magnesium insufficiency and AF [4][10] Comparative Effectiveness - A recent study indicated that the ePatch detected 2x more clinically significant heart arrhythmias during 7 days of monitoring and over 2.5x as many during 14 days compared to conventional 24-hour Holter monitoring [7]